Response to Alpelisib in an Adolescent With PIK3CA-Mutated Metastatic Gastrointestinal Stromal Tumor

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00105 JCO Precision Oncology no. 6 (2022) e2200105. Published online August 2, 2022. PMID: 35917491 Response to Alpelisib in an Adolescent With PIK3CA-Mutated Metastatic Gastrointestinal Stromal Tumor Sarah Cohen-Gogo , MD, PhD1xSarah Cohen-GogoSearch for articles by this author; Nisha Kanwar, PhD2xNisha KanwarSearch for articles by this author; Furqan Shaikh , MD, MSc1xFurqan ShaikhSearch for articles by this author; Reto M. Baertschiger, MD, PhD3xReto M. BaertschigerSearch for articles by this author; Adam Shlien , PhD2xAdam ShlienSearch for articles by this author; David Malkin , MD1xDavid MalkinSearch for articles by this author; Juan Putra , MD4xJuan PutraSearch for articles by this author; Ailish Coblentz , MD5xAilish CoblentzSearch for articles by this author; Anita Villani , MD1xAnita VillaniSearch for articles by this author; Abha A. Gupta, MD, MSc1xAbha A. GuptaSearch for articles by this author; and Daniel A. Morgenstern , MD, PhD1xDaniel A. MorgensternSearch for articles by this author Show More 1Division of Hematology/Oncology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada2Division of Pathology and Laboratory Medicine, The Hospital for Sick Children, Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada3Division of General and Thoracic Surgery, The Hospital for Sick Children, Department of Surgery, University of Toronto, Toronto, ON, Canada4Department of Pathology, Boston Children's Hospital, Boston, MA5Diagnostic Imaging, The Hospital for Sick Children, Toronto, ON, Canada https://doi.org/10.1200/PO.22.00105 First Page Full Text PDF Figures and Tables Supplements © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Sarah Cohen-Gogo, Furqan Shaikh, David Malkin, Abha A. Gupta, Daniel A. MorgensternFinancial support: Adam ShlienProvision of study materials or patients: Sarah Cohen-Gogo, Reto M. Baertschiger, Adam Shlien, Daniel A. MorgensternCollection and assembly of data: Sarah Cohen-Gogo, Reto M. Baertschiger, Adam Shlien, Juan Putra, Anita Villani, Daniel A. MorgensternData analysis and interpretation: Sarah Cohen-Gogo, Nisha Kanwar, Adam Shlien, David Malkin, Ailish Coblentz, Anita Villani, Abha A. Gupta, Daniel A. MorgensternManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).David MalkinConsulting or Advisory Role: BayerDaniel A. MorgensternHonoraria: Ology Medical Education, WebMD, PlatformQ HealthConsulting or Advisory Role: Clarity Pharmaceuticals, EUSA Pharma, Y-mAbs Therapeutics, IncSpeakers' Bureau: Y-mAbs Therapeutics, IncResearch Funding: Bristol Myers Squibb (Inst), AbbVie (Inst), Lilly (Inst), Bayer (Inst), Cellectar (Inst), Roche (Inst)Travel, Accommodations, Expenses: LillyNo other potential conflicts of interest were reported.